So here's something you don't see every day: the President of the United States is putting serious money behind psychedelic research. On Saturday, President Donald Trump signed an executive order telling the U.S. Food and Drug Administration to move faster on reviews for psychedelic-based treatments. The headline act is ibogaine, a substance veteran advocates believe could help with post-traumatic stress disorder.
And he's not just asking nicely—he's putting cash on the table. At an Oval Office event, Trump said the federal government would commit $50 million for ibogaine research. FDA Commissioner Marty Makary said the agency could have determinations ready as soon as this summer. That's a pretty tight timeline for the federal bureaucracy.
This push on mental health care comes alongside a separate, more mundane but potentially impactful effort: a new website aimed at bringing down drug prices. The site, trumprx.gov, is essentially a search-and-coupon tool. You look up a drug, see a reduced price, and print a coupon to redeem at your pharmacy or through manufacturers' online channels. It doesn't dispense medications itself; it just helps you find a better deal.
The White House says 40 medicines from five companies are already listed on the site, thanks to "most-favored-nation" pricing arrangements. The participating companies include AstraZeneca PLC (AZN), Eli Lilly And Co. (LLY), EMD Serono, Novo Nordisk (NVO), and Pfizer Inc. (PFE). Some of the clearest examples involve GLP-1 drugs for diabetes and obesity—Ozempic and Wegovy are shown dropping from over $1,000 per month to as low as $199, depending on the dose. Fertility drugs like Gonal-F and Cetrotide are also flagged for lower costs.
Meanwhile, back in the world of psychedelics, the administration is making a calculated bet. Health Secretary Robert F. Kennedy Jr. has backed using ibogaine and similar substances as alternatives for mental health conditions like depression. Administration officials say they believe the scientific record has reached a point where ibogaine's potential as a therapy can be seriously considered, even though these drugs are largely illegal and can trigger hallucinations.
Trump framed the shift as a break from past stigma. "I've been hearing about it a little bit over the last year," he said. "I never heard anything about it in the past. It was almost like, taboo. It's not taboo anymore." That same willingness to challenge norms is showing up in the drug-pricing playbook, which focuses on steering consumers toward lower sticker prices rather than changing prescriptions themselves.
According to reports, the executive order tells the FDA to accelerate its work on drugs like ibogaine, and federal officials say the changes are designed to open a path for reclassification if clinical trials succeed. The regulatory adjustments are intended to make it possible for these substances to be rescheduled after trials demonstrate safety and effectiveness.
This isn't happening in a vacuum. The psychedelic therapeutics market is projected to reach $8.75 billion by 2031, growing at a compound annual rate of 13.55%. Companies are positioning themselves for this emerging field. For instance, Psyence BioMed has secured GMP-compliant production capabilities for both psilocybin and ibogaine through its investment in PsyLabs. The company's CEO, Jody Aufrichtig, emphasized that "infrastructure is strategy," reflecting a broader trend where firms with standardized pharmaceutical manufacturing are poised to generate durable enterprise value.
On the regulatory side, the Department of Labor has proposed rules aimed at forcing Pharmacy Benefit Managers to reveal how they are paid by self-insured group health plans—a market that covers about 90 million Americans. While the pricing initiative targets household budgets, the psychedelic order is aimed at speeding the research-to-treatment timeline for conditions that have been tough to manage with standard approaches.
So, what's the big picture? The administration is pushing on two fronts: making existing drugs cheaper through coupons and negotiations, while also fast-tracking research into entirely new kinds of treatments. Veteran organizations have argued that ibogaine could be useful for PTSD, and the $50 million research commitment specifically targets that substance. The goal is to generate more clinical evidence alongside the regulatory push.
In parallel, the broader health agenda leans on negotiated manufacturer discounts and coupon-style access through trumprx.gov, with the aim of narrowing the gap between U.S. drug prices and what patients pay in other countries. The administration says more medicines from additional companies that struck "MFN pricing deals" are expected to appear on the site in the coming months.
It's a fascinating moment. You have a president funding research into a once-taboo substance while also launching a website to hand out drug coupons. One effort looks to the future of mental health treatment; the other tries to fix the present-day cost of prescriptions. Whether either works remains to be seen, but they're certainly not playing it safe.
